United Therapeutics Corporation $UTHR Stock Holdings Lowered by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 2.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 512,739 shares of the biotechnology company’s stock after selling 15,471 shares during the period. Dimensional Fund Advisors LP’s holdings in United Therapeutics were worth $304,029,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Norges Bank acquired a new stake in shares of United Therapeutics during the 4th quarter valued at $293,418,000. Avoro Capital Advisors LLC boosted its stake in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares in the last quarter. Finally, Baillie Gifford & Co. acquired a new position in shares of United Therapeutics in the 4th quarter worth $157,390,000. 94.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,890,130.68. This represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 525,743 shares of company stock worth $293,954,527. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $644.82.

United Therapeutics Stock Down 1.6%

Shares of United Therapeutics stock opened at $527.07 on Thursday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a market cap of $22.37 billion, a PE ratio of 19.46, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58. The business has a fifty day simple moving average of $549.61 and a 200-day simple moving average of $531.18.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $6.63 earnings per share. Analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.